Bookmark and Share

Pluristem Therapeutics, Inc. (PSTI) is Commercializing Profound New Approach to Therapeutics

There are so many significant developments occurring in the medical industry on a regular basis that it’s almost impossible for an investor to separate out those that are truly profound and have long term implications. Some companies, however, are doing things that are clearly in that camp, developing therapeutic approaches that could revolutionize the treatment and prevention of whole classes of diseases.

Pluristem Therapeutics is a bio-therapeutic company working with what are called allogenic (unrelated donor-patient) cell therapy products. The company is creating a pipeline of products derived from human placenta, a non-controversial and non-embryonic adult stem cell source. These cells possess immunomodulatory properties, protecting the recipient from immunological reactions and requiring no histocompatibility matching.

Once produced, these PLX (PLacental eXpanded) cell products are stored and ready-to-use for the treatment of a variety of severe diseases where current therapies are unavailable or inadequate. Although Pluristem is currently focusing on a few specific but significant products and diseases, the potential range of applications is far greater.

PLX-PAD, Pluristem’s first product, targets an annual $4 billion market, and is intended to treat patients suffering from the critical stage of peripheral artery disease (PAD), where blood supply is restricted to organs or extremities.

PLX-BMT, Pluristem’s second product, targets an annual $2 billion market, and is intended to resolve the global shortfall of matched hematopoietic (blood forming) stem cells for bone marrow transplantation. (Approximately 60% of leukemia patients are unable to find suitable bone marrow donors.)

PLX-STROKE targets an annual $4 billion market, and shows potential to become a new treatment for the functional recovery from an ischemic stroke. This is the most common kind of stroke, and is caused by an interruption in the flow of blood to the brain (as from a clot blocking a blood vessel).

In addition, Pluristem already has animal data suggesting its PLX cells are of value in meeting an unmet need in the treatment of other disorders such as Multiple Sclerosis )MS) and Crohn’s Disease. Moreover, the company believes its PLX cells are also potentially useful for such things as organ transplantation, orthopedic injuries, and the prevention of radiation sickness.

For more information visit

Friday, February 18th, 2011 Uncategorized
Top Small Cap Market News